secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001213900-24-030466
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt signs agreement to acquire Appili Therapeutics for $5.7M cash plus stock
-------------------------------------------------------------------------------

- Acquisition for ~$5.7M cash plus ~332,876 Aditxt shares; ~$0.0467/sh + 0.002745 ADTX share per Appili share.
- Assets include FDA-approved LIKMEZ, DoD-funded ATI-1701 tularemia vaccine ($14M award), and ATI-1801 topical leishmaniasis treatment.
- Closing conditioned on Aditxt raising at least $20M financing by June 30, 2024; termination fee of CDN$1.25M if not met.
- Transaction requires Appili shareholder vote, court approval, and NASDAQ listing of Consideration Shares.
- Outstanding Appili options/warrants cashed out for additional ~$341,000 aggregate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/0001213900-24-030466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/ea0203328-8k_aditxtinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-030466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer